A Healthy Brain For Life - RESI Longevity
Transcript of A Healthy Brain For Life - RESI Longevity
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
A Healthy Brain For Life
Dementia - The #1 health concern for 42% of population.
Mitocholine™ in the daily diet for a healthy brainthroughout life
Unique Investment Opportunity in Cognitive Decline Market
Mitocholine™ -
A BreakthroughNew
Compound
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
The ProblemAgeing Population escalates numbers suffering
from Dementia
Source: Alzheimers Research UK
50,000,000
150,000,000
0
40
80
120
160
Y2019 Y2050
Milli
ons
of P
eopl
e
Region Economic Cost of Dementia (2018)
UK £26bn
EU €220bn
US $290bn
AsiaPac $200bn
Globally $1000bn
Spiralling Economic Cost
$6600bn by
Y2050
Ø Nobody knows WhoØ Everybody’s at risk
Ø No Present SolutionØ Huge unmet Need
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
200,000,000
700,000,000
Dementia
Cognitive Impairment
Worried Well
Our Target Markets50,000,000
The OpportunityDementia #1 Health Concern for 42% of Population
Sources: Alzheimers Research UK and Pew Research Center
1
2
Huge market: Ø Population with early stage cognitive declineØ Those very concerned (42% of Population)
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
The Science
Source: Stephen C. Cunnane et al, Brain Energy Rescue, Nature Review
Mitocholine™ addresses dysfunctional brain cell energetics, a key factor in cognitive decline
https://youtu.be/qIohuf6k82QExplanatory video:
Brain energy gap
Brain cell dysfunction
Ø AgeØ LifestyleØ Genes
Ø Memory lossØ MCIØ Dementia
Increases
Increases
MitocholineTM breaks the vicious cycle by
rescuing brain energy
Vicious..
..Cycle
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
The SolutionMitocholine™ Choline Succinate salt Nicotinamide= : +
ATP NADH
Patented Ratio
BreakthroughSynergistic
Effect
Pre-clinical Findings Pre-clinical Findings
Mitocholine™ dramatically improves key markers of mitochondrial energy production
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
IP Protection• Patent Application Filed 2017
• IPA* search found invention novel & non-obvious
• Patent Grants expected from 2022
• Freedom to Operate
• IP Protection until 2038*IPA – International Patent Authority
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
CommercialisationPrimary target markets are medical foods/FSMP and nutritional products
Medicated Gummies& Lozenges
Capsules& tablets*
*Requires R&D for powdered production
Ø Nutritional approach ideally suited for long-term-, chronic interventions...
Ø ...with high-end categories by strategic partners with global reach
Nutritional Dairy Products
MedicatedDrinks
NutritionalBeverages
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
Route to MarketPatent Protection
2019 2020 2021 2022 2023 2024 2025
US GRAS/EFSA Novel Food Dossier & ApprovalRound A Fund Raising (Venture Arms Strategic Partner Candidates)
Launch Product
Patent Approval
Clinical Trials PoC(MCI Patients)
WO 2019/002858
2026 2027
Prod. Dev. w/Strategic Partners
Commercial/Sales to Strategic Partners
Submitted
1 2 3 4
1 US
2 UK
3 EU5
4 AsiaPac
(Order may change)
Medical Foods/FSMP much quicker than Pharma
route
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
Attractive Business Plan
-
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
200,000
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Unit Sales(x 1,000)
US UK EU5 APAC
Based on standard medical food values and Kantar Health models
Reason to believe: 2031 sales represents a realistic penetration of 2.6% of mild cognitive impairment market
Based on normative Medical Food/FSMP assumptions
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
-
50,000
100,000
150,000
200,000
250,000
300,000
350,000
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Retail Revenue(x £1,000)
US UK EU5 APAC
× 15 ≈ £120m valuationRound A
£3m
Ø Investment of £3 million required to complete clinical trial and regulatory approvalsØ Exit opportunities in 3 to 5 years upon completion of 1st clinical study and initial partnership deals
Attractive Business PlanBased on normative Medical Food/FSMP assumptions
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
The Team Who Can Deliver
Daniel AnthonyProfessor Oxford
Andrey AbramovProfessor UCL
Advisory Board
Key Collaborators
20+ years of experience in FMCG and nutrition companies, including:• Formulating and executing corporate
innovation and IP strategies• Starting and growing businesses• Leading multifunctional teams
involving research, marketing, finance, IP and M&A.
(Nestlé, Glycom)
Bruce McConnellChairman of the Board
Simon BaldryCOO
More than 20 years of experience as Managing Director / General Manager in the Food & Drink Industry(Coca Cola, Cadbury)
Larisa Andreeva, PhD, Founder/CEO
25 years experience from biochemresearch and research programmemanagement (Imperial College London, UCL)
Igor Pomytkin, PhD, Founder/Chief Scientist
35+ years experience in neuroscientific research. More than 30 patents to his name (University of Oxford, University of Moscow) of which several have become commercial products.
Galina SkladchikovaPhD, Founder,
Head of IP
20+ years experience in:• Scientific research in the fields of
biochemistry, molecular and cell biology;
• Strategic IP development and management;
• Implementation of IP in innovation and business;
(Glycom, Dako, Hoiberg).Christian Barnes
Dir. Licensing
15yrs experience in product innovation and business development, including BD director of Nestle Health's Science Brain Health platform (Pamlab, Nestle, Akebia)
Prototype Dev. & Testing
Clinical Trials
Regulatory Specialist
© 2020 Mitocholine Ltd - All rights reserved
Mitocholine™
For further info please contact :Larisa Andreeva at [email protected]
Thank you!
A Healthy Brain For LifeØ Will deliver massive
improvement in quality of life for patient and family
Ø A high-, unmet-, growing need.
Ø A breakthrough solution with excellent initial data and IP.
Ø Unparallelled benefits for society
Ø Lower risk-, rapid (non-pharma) route to market.
Ø A team who can deliver
Ø Many-fold ROI opportunity with superb exit opportunity in 3 to 5 years.